IKZF3

Across TCGA pan-cancer cohorts, IKZF3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IKZF3 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher IKZF3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IKZF3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, ACC, and UCEC are the cancer types where IKZF3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	All	0.154	0.904	<.001	39	view →
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
UCEC	DFS	Median	II,III,IV	1.000	0.436	.010	32	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	18	view →
LAML	DFS	Median	All	0.028	0.572	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IKZF3–DLBC (OS)

Open the DLBC breakdown →